Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Is anti-inflammatory therapy for type 2 diabetes mellitus ready for routine clinical practice?

Nature Clinical Practice Endocrinology & Metabolism volume 3, pages 806–807 (2007)Cite this article

boxed-textLarsen CM et al. (2007) Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 356: 1517–1526

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Ritzel RA et al. (2006) Relationship between ß-cell mass and fasting blood glucose concentration in humans. Diabetes Care 29: 717–718

    Article  Google Scholar 

  2. Ehses JA et al. (2007) Increased number of islet-associated macrophages in type 2 diabetes. Diabetes 56: 2356–2370

    Article  CAS  Google Scholar 

  3. Maedler K et al. (2002) Glucose-induced ß cell production of IL-1ß contributes to glucotoxicity in human pancreatic islets. J Clin Invest 110: 851–860

    Article  CAS  Google Scholar 

  4. Welsh N et al. (2005) Is there a role for locally produced interleukin-1 in the deleterious effects of high glucose or the type 2 diabetes milieu to human pancreatic islets? Diabetes 54: 3238–3244

    Article  CAS  Google Scholar 

  5. Worrall BB et al. (2007) IL1RN VNTR polymorphism in ischemic stroke: analysis in 3 populations. Stroke 38: 1189–1196

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Vicky Heath, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. and JL Nadler is the Chief of the Division of Endocrinology and Metabolism at the University of Virginia, NA Maybee is an Endocrine Fellow, BB Worrall is an Assistant Professor of Neurology and Public Health Sciences, Charlottesville, VA, USA.,

    Nelly A Maybee, Bradford B Worrall & Jerry L Nadler

Authors
  1. Nelly A Maybee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bradford B Worrall
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jerry L Nadler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jerry L Nadler.

Ethics declarations

Competing interests

Jerry L Nadler is the Director of DiaKine Therapeutics, a member of the Merck Speakers Bureau, and has received research support from Merck and Novartis. The other authors declared no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Maybee, N., Worrall, B. & Nadler, J. Is anti-inflammatory therapy for type 2 diabetes mellitus ready for routine clinical practice?. Nat Rev Endocrinol 3, 806–807 (2007). https://doi.org/10.1038/ncpendmet0645

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpendmet0645

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing